Related Experiment Video
Updated: May 9, 2026
Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
Published on: September 26, 2013
[Th17-mediated relapsing-remitting multiple sclerosis is nonresponsive to interferon-β1b]
Xiaoyan Zhang1, Qi Zhang, Xiangqun Shi
1Department of Neurology, Lanzhou General Hospital, Lanzhou Military Region, Lanzhou 730050, China.
Objective:
To investigate the relationship between the efficacy of interferon beta-1b (INF-β-1b) on relapsing-remitting multiple sclerosis (RRMS) and the Th17 cells in peripheral blood.
Methods:
Eleven RRMS patients were enrolled and treated with 250 μg INF-β-1b for 6 months. Expanded disability status scale (EDSS) scrore and T2 lesion number on MRI were examined both at baseline and at the end of the study. Flow cytometry was used to detect the number of Th17 cells in peripheral blood before the treatment.
Results:
Acoording to the EDSS scores, the 11 cases of RRMS were divided into two groups: the effective group and the ineffective group.The EDSS scores and the number of lesions on T2-weighted MRI were not different significantly between the two groups (P>0.05) before the treatment. But after the treatment, compared with the ineffective group, the EDSS scores and the number of lesions on T2-weighted MRI decreased significantly in the effective group (P<0.05). Compared with the effective group, the number of Th17 cells in the ineffective group increased significantly (P<0.01) before treatment.
Conclusion:
Th17-mediated RRMS is nonresponsive to IFN-β-1b treatment.
Related Concept Videos
01:24T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents